SCHEMBL9890720

SCHEMBL9890720

NC(=O)Cc1ccccc1-c1cccc(Cl)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.47
DPP4 P27487 1/20 0.44
PNMT P11086 1/20 0.44
KMT2A Q03164 2/20 0.42
APAF1 O14727 1/20 0.42
TDP2 O95551 1/20 0.42
NSD2 O96028 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
SAE1 Q9UBE0 1/20 0.42
UBA2 Q9UBT2 1/20 0.42
CTBP2 P56545 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
SLC9A1 P19634 1/20 0.40
KCNJ5 P48544 1/20 0.40
KCNJ3 P48549 1/20 0.40
MAPK8 P45983 1/20 0.40
IDO1 P14902 2/20 0.40
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2394862 0.88 DPP4 (0.58) PKMDPP4PNMTKMT2AAPAF1
SCHEMBL3393837 0.86 PNMT (0.59) PKMPNMTKMT2AALDH1A1MAPT
SCHEMBL29760897 0.86 PNMT (0.59) PKMPNMTKMT2AALDH1A1MAPT
SCHEMBL9890643 0.85 CXCL8 (0.54) CTBP2ADRA1ACYP2C9AKR1B10UGT1A9
SCHEMBL2395681 0.84 PDCD1 (0.41) KMT2AALDH1A1MAPTLMNACYP2C19
SCHEMBL9890745 0.84 CHRM1 (0.43) PKMDPP4KMT2AAPAF1TDP2
SCHEMBL1091961 0.84 PKM (0.64) PKMPNMTKMT2AAPAF1TDP2
SCHEMBL2394150 0.83 PKM (0.40) PKMDPP4KMT2AAPAF1TDP2
Hydrochloric Acid SCHEMBL7827446 0.82 PKM (0.62) PKMPNMTKMT2AAPAF1TDP2
SCHEMBL18302007 0.80 PTGS2 (0.44) PKMDPP4KMT2AAPAF1TDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PKM 3929/4885DPP4 3177/4885PNMT 572/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PKM 3929/4885DPP4 3177/4885PNMT 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.